Sonrotoclax
Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines[1].
Product Specifications
CAS Number
[2383086-06-2]
Product Name Alternative
BGB 11417
UNSPSC
12352005
Target
Bcl-2 Family
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sonrotoclax.html
Concentration
10mM
Purity
99.61
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC(C1=C(C=CC=C1)[C@H]2N(CCC2)C3CC4(CCN(C5=CC(OC6=CN=C(NC=C7)C7=C6)=C(C=C5)C(NS(=O)(C8=CC([N+]([O-])=O)=C(C=C8)NC[C@@H]9CC[C@@](O)(CC9)C)=O)=O)CC4)C3)C
Molecular Formula
C49H59N7O7S
Molecular Weight
890.10
References & Citations
[1]Nan HU, et, al. Methods of cancer treatment using bcl-2 inhibitor. WO2021110102A1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
(5alpha,10alpha,17beta)-5,10-Epoxy-17-hydroxy-17-(1-propyn-1-yl)-estr-9(11)-en-3-one Cyclic 1,2-Ethanediyl Acetal